TY - JOUR T1 - Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 41 LP - 51 DO - 10.1124/dmd.119.089151 VL - 48 IS - 1 AU - Zheng Li AU - You Gao AU - Chunmiao Yang AU - Yanan Xiang AU - Wenpeng Zhang AU - Tianhong Zhang AU - Ruibin Su AU - Chuang Lu AU - Xiaomei Zhuang Y1 - 2020/01/01 UR - http://dmd.aspetjournals.org/content/48/1/41.abstract N2 - Atipamezole, an α2-adrenoceptor antagonist, displayed nonlinear pharmacokinetics (PK) in rats. The aim of this study was to understand the underlying mechanisms of nonlinear PK in rats and linear PK in humans and develop physiologically based PK models (PBPK) to capture and validate this phenomenon. In vitro and in vivo data were generated to show that metabolism is the main clearance pathway of atipamezole and species differences exist. Where cytochrome P450 (P450) was responsible for the metabolism in rats with a low Michaelis constant, human-specific UDP-glucuronosyltransferase 2B10– and 1A4–mediated N-glucuronidation was identified as the leading contributor to metabolism in humans with a high Vmax capacity. Saturation of metabolism was observed in rats at pharmacologically relevant doses, but not in humans at clinically relevant doses. PBPK models were developed using GastroPlus software to predict the PK profile of atipamezole in rats after intravenous or intramuscular administration of 0.1 to 3 mg/kg doses. The model predicted the nonlinear PK of atipamezole in rats and predicted observed exposures within 2-fold across dose levels. Under the same model structure, a human PBPK model was developed using human in vitro metabolism data. The PBPK model well described human concentration–time profiles at 10–100 mg doses showing dose-proportional increases in exposure. This study demonstrated that PBPK is a useful tool to predict human PK when interspecies extrapolation is not applicable. The nonlinear PK in rat and linear PK in human were characterized in vitro and allowed the prospective human PK via intramuscular dosing to be predicted at the preclinical stage.SIGNIFICANCE STATEMENT This study demonstrated that PBPK is a useful tool for predicting human PK when interspecies extrapolation is not applicable due to species unique metabolism. Atipamezole, for example, is metabolized by P450 in rats and by N-glucuronidation in humans that were hypothesized to be the underlying reasons for a nonlinear PK in rats and linear PK in humans. This was testified by PBPK simulation in this study. ER -